BioSpace News Archive

Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response (DDR) technologies, is pleased to announce that it has been invited to present at the Emerging Growth Conference on Wednesday, November 30, 2022, at 10:15am Eastern standard time.

The field of proteomics is set to be revolutionised with the launch of IonOpticks’ Aurora Frontier that achieves more than 10,000 proteins per sample.

GNS today announced two abstracts and two oral poster presentations highlighting insight from the Gemini Digital Twin models in Alzheimer’s Disease and Multiple Myeloma will be included at the Clinical Trials on Alzheimer’s Disease conference (CTAD) in San Francisco and the American Society of Hematology (ASH) in New Orleans.

According to Vision Research Reports, the global pyrogen testing market size surpassed at US$ 0.94 billion in 2021 and is expected to grow at a CAGR of 12.5% from 2022 to 2030.

The Global Artificial Red Blood Cells market is forecasted to grow at a rate of 21.1% from USD 4.12 billion in 2019 to USD 19.11 billion in 2030.

The global geriatric medicine market size was valued at US$ 769.96 billion in 2021 and is expected to grow at a CAGR of 6.8% over forecast period 2022 to 2030.

The Series B funding was extended by 25 million euros to reach a total of 42 million euros The new funding enables a further expansion of the Temedica ecosystem, which provides holistic insights into the care realities and patient journeys of millions of patients by combining health-related data Temedica leads the way in extracting valuable insights from anonymized health data for all healthcare stakeholders in a GDPR-compliant manner MUNICH, Germany, Nov. 23, 2022 (GLOBE NEWSWIRE) --

Bright Minds Biosciences today announced that Mark A. Smith M.D., Ph.D. will join the Company as Chief Medical Officer, effective December 1, 2022.

Ryvu Therapeutics today announced third quarter 2022 financial results and provided a corporate update.

Pharming Group N.V. announces that new clinical data for leniolisib will be presented by V. Koneti Rao, MD, FRCPA, staff physician in the Primary Immune Deficiency Clinic at the National Institute of Health in Bethesda, Maryland, at the 64th American Society of Hematology Annual Meeting and Exposition, in New Orleans, Louisiana taking place from Saturday, December 10 through Tuesday, December 13, 2022.